Emma C Tallantyre
Overview
Explore the profile of Emma C Tallantyre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gelissen L, Loveless S, Toorop A, Howlett J, Loeff F, Rispens T, et al.
Mult Scler Relat Disord
. 2024 Aug;
90:105796.
PMID: 39096666
Background: Several studies reported lower drug concentrations with subcutaneous natalizumab compared to intravenous natalizumab. With the emergence of extended interval dosing, gaining more insight into lower concentrations after subcutaneous administration...
2.
Tallantyre E, Dobson R, Froud J, St John F, Anderson V, Arun T, et al.
Eur J Neurol
. 2024 Apr;
31(7):e16289.
PMID: 38567516
Background And Purpose: Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real-world rates of persistence on...
3.
Uzochukwu E, Harding K, Hrastelj J, Kreft K, Holmans P, Robertson N, et al.
Neuroepidemiology
. 2024 Feb;
58(3):218-226.
PMID: 38377969
Objectives: The objective of this study was to model multiple sclerosis (MS) disease progression and compare disease trajectories by sex, age of onset, and year of diagnosis. Study Design And...
4.
Kodosaki E, Watkins W, Loveless S, Kreft K, Richards A, Anderson V, et al.
J Neuroinflammation
. 2024 Feb;
21(1):52.
PMID: 38368354
Establishing biomarkers to predict multiple sclerosis diagnosis and prognosis has been challenging using a single biomarker approach. We hypothesised that a combination of biomarkers would increase the accuracy of prediction...
5.
Kreft K, Uzochukwu E, Loveless S, Willis M, Wynford-Thomas R, Harding K, et al.
Ann Neurol
. 2023 Nov;
95(3):459-470.
PMID: 37974536
Objective: Currently, 233 genetic loci are known to be associated with susceptibility to multiple sclerosis (MS). Two independent pivotal severity genome-wide association studies recently found the first genome-wide significant single-nucleotide...
6.
Zaloum S, Wood C, Tank P, Upcott M, Vickaryous N, Anderson V, et al.
Mult Scler
. 2023 Jul;
29(8):979-989.
PMID: 37431627
Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear. Objective: To report COVID-19 rates...
7.
Cauchi M, Willis M, Andrews A, Backx M, Brownlee W, Ford H, et al.
Pract Neurol
. 2022 Jul;
PMID: 35863879
Infection in people with multiple sclerosis (MS) is of major concern, particularly for those receiving disease-modifying therapies. This article explores the risk of infection in people with MS and provides...
8.
Garjani A, Liu B, Allen C, Gunzler D, Gerry S, Planchon S, et al.
Mult Scler
. 2022 Jun;
29(3):317-325.
PMID: 35735014
Randomised controlled trials (RCTs) play an important role in multiple sclerosis (MS) research, ensuring that new interventions are safe and efficacious before their introduction into clinical practice. Trials have been...
9.
Tallantyre E, Scurr M, Vickaryous N, Richards A, Anderson V, Baker D, et al.
Mult Scler Relat Disord
. 2022 Jun;
64:103937.
PMID: 35700625
Background: People with MS treated with anti-CD20 therapies and fingolimod often have attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the benefit of a 3rd (booster) COVID-19 vaccine...
10.
Topcu G, Smith L, Mhizha-Murira J, Goulden N, Hoare Z, Drummond A, et al.
Pilot Feasibility Stud
. 2022 Jun;
8(1):123.
PMID: 35690797
Background: Cognitive problems affect up to 70% of people with multiple sclerosis (MS), which can negatively impact mood, ability to work, and quality of life. Addressing cognitive problems is a...